Arovella Therapeutics Ltd
ASX:ALA
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.088
0.205
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Arovella Therapeutics Ltd
Arovella Therapeutics Ltd
Revenue
Arovella Therapeutics Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Arovella Therapeutics Ltd
ASX:ALA
|
Revenue
AU$155.7k
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-34%
|
CAGR 10-Years
N/A
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Revenue
AU$395.5m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Revenue
AU$204.2m
|
CAGR 3-Years
1 234%
|
CAGR 5-Years
71%
|
CAGR 10-Years
48%
|
|
|
Botanix Pharmaceuticals Ltd
ASX:BOT
|
Revenue
AU$677.5k
|
CAGR 3-Years
87%
|
CAGR 5-Years
28%
|
CAGR 10-Years
42%
|
|
|
Probiotec Ltd
ASX:PBP
|
Revenue
AU$221.2m
|
CAGR 3-Years
28%
|
CAGR 5-Years
24%
|
CAGR 10-Years
13%
|
|
|
Vita Life Sciences Ltd
ASX:VLS
|
Revenue
AU$78.9m
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
8%
|
|
Arovella Therapeutics Ltd
Glance View
Arovella Therapeutics Ltd. develops pharmaceuticals and distributes medical devices and consumables. The company is headquartered in Perth, Western Australia. The company went IPO on 2002-01-24. The firm focuses on specific disease areas, oncology and conditions that affect the central nervous system. The company is focused on developing therapies to treat human disease. The firm is developing its invariant natural killer T (iNKT) cell therapy platform to treat blood cancers. The firm's OroMist technology develops oral sprays to reformulate pharmaceuticals. Its ZolpiMist oral spray formulation of zolpidem tartrate to treat short-term insomnia. The company is also developing oral sprays to treat migraine headaches, motion sickness, and drug-resistant epilepsy.
See Also
What is Arovella Therapeutics Ltd's Revenue?
Revenue
155.7k
AUD
Based on the financial report for Jun 30, 2024, Arovella Therapeutics Ltd's Revenue amounts to 155.7k AUD.
What is Arovella Therapeutics Ltd's Revenue growth rate?
Revenue CAGR 5Y
-34%
Over the last year, the Revenue growth was -64%. The average annual Revenue growth rates for Arovella Therapeutics Ltd have been -16% over the past three years , -34% over the past five years .
You don't have any saved screeners yet
